Product Description
Mechanisms of Action: PNP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral,Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Japan
Approved Indications: None
Known Adverse Events: None
Company: BioCryst
Company Location: DURHAM NC 27703
Company CEO: Jon P. Stonehouse
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: T-Cell Cutaneous Lymphoma|Arthritis, Rheumatoid|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, B-Cell|T-Cell Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Chronic Lymphoid Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|B-Cell Leukemia|Lymphocytic Chronic B-Cell Leukemia|Type 2 Diabetes|Osteoarthritis|Lymphoma|Acute Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Lymphoid Leukemia|Leukemia|T-Cell Peripheral Lymphoma|T-Cell Lymphoma|Burkitt Lymphoma
Phase 1: T-Cell Cutaneous Lymphoma|Hairy Cell Leukemia|Liver Cirrhosis|Chronic Myeloid Leukemia|Prolymphocytic Leukemia|Granular Cell Tumor|Lymphocytic Chronic B-Cell Leukemia|Large Cell Carcinoma|Esophageal Cancer|Glioblastoma|Acute Monocytic Leukemia|Mycosis Fungoides|Prolymphocytic T-Cell Leukemia|NUT Carcinoma|Follicular Adenocarcinoma|Follicular Lymphoma|Acute Eosinophilic Leukemia|Central Nervous System Cancer|Pancreatic Cancer|Prolymphocytic B-Cell Leukemia|Brain Stem Cancer|Ovarian Cancer|Leukemia, Neutrophilic, Chronic|Oncology Unspecified|Sarcoma, Myeloid|Myelofibrosis|Diffuse Large B-Cell Lymphoma|Myelodysplastic Syndrome|Liver Cancer|Thrombocythemia, Essential|Acute Lymphoid Leukemia|Primary Central Nervous System Lymphoma|Melanoma|Abnormalities, Multiple|Colorectal Cancer|Polycythemia Vera|Acute Myelomonocytic Leukemia|Gastrointestinal Cancer|Bile Duct Cancer|Intraocular Lymphoma|Primary Cutaneous Anaplastic Large Cell Lymphoma|Multiple Myeloma|Sezary Syndrome|Giant Cell Carcinoma|Lymphoma, Non-Hodgkin|Chronic Lymphoid Leukemia|Chronic Myelomonocytic Leukemia|Ependymoma|Chronic, Atypical, BCR-ABL Negative Myeloid Leukemia|Burkitt Lymphoma|Gliosarcoma|B-Cell Marginal Zone Lymphoma|Splenic Cancer|Astrocytoma|Acute Myeloid Leukemia|Large Granular Lymphocytic Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JapicCTI-121985 | P2 |
Completed |
T-Cell Peripheral Lymphoma |
2016-12-31 |
|
| FDS-J02 | P2 |
Completed |
T-Cell Peripheral Lymphoma |
2016-03-01 |
|
| BCX1777-J01 | P1 |
Completed |
Oncology Unspecified |
2013-08-01 |
|
| forodesine in CTCL | P2 |
Completed |
T-Cell Cutaneous Lymphoma |
2011-12-07 |